Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies
Oncologic immunotherapy involves stimulating the immune system to more effectively identify and eradicate tumor cells that have successfully adapted to survive the body's natural immune defenses. Immunotherapy has shown great promise thus far by prolonging the lives of patients with a variety o...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
AIMS Press
2015-03-01
|
Series: | AIMS Public Health |
Subjects: | |
Online Access: | http://www.aimspress.com/aimsph/article/226/fulltext.html |
id |
doaj-56ee4172a4fa406d89c2d4d43db8719b |
---|---|
record_format |
Article |
spelling |
doaj-56ee4172a4fa406d89c2d4d43db8719b2020-11-24T21:40:20ZengAIMS PressAIMS Public Health2327-89942015-03-01218611410.3934/publichealth.2015.1.8620150108Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary MalignanciesAlexander B. Dillon0Kevin Lin1Andrew Kwong2Susana Ortiz3Mount Zion Cancer Research Center, Department of Dermatology, University of California San Francisco, CA 94141, USAMount Zion Cancer Research Center, Department of Dermatology, University of California San Francisco, CA 94141, USAMount Zion Cancer Research Center, Department of Dermatology, University of California San Francisco, CA 94141, USAMount Zion Cancer Research Center, Department of Dermatology, University of California San Francisco, CA 94141, USAOncologic immunotherapy involves stimulating the immune system to more effectively identify and eradicate tumor cells that have successfully adapted to survive the body's natural immune defenses. Immunotherapy has shown great promise thus far by prolonging the lives of patients with a variety of malignancies, and has added a crucial new set of tools to the oncologists' armamentarium. The aim of this paper is to provide an overview of immunotherapy treatment options that are currently available and under active research for melanoma, gastrointestinal (esophageal, gastric, pancreatic, and colorectal), and pulmonary malignancies. Potential biomarkers that may predict favorable responses to immunotherapies are discussed where applicable, as are future avenues of research in this rapidly evolving field.http://www.aimspress.com/aimsph/article/226/fulltext.htmlimmunotherapymelanomaesophageal cancergastric cancercolorectal cancerlung cancerIL-2adoptive cell therapyanti-CTLA-4anti-PD-1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alexander B. Dillon Kevin Lin Andrew Kwong Susana Ortiz |
spellingShingle |
Alexander B. Dillon Kevin Lin Andrew Kwong Susana Ortiz Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies AIMS Public Health immunotherapy melanoma esophageal cancer gastric cancer colorectal cancer lung cancer IL-2 adoptive cell therapy anti-CTLA-4 anti-PD-1 |
author_facet |
Alexander B. Dillon Kevin Lin Andrew Kwong Susana Ortiz |
author_sort |
Alexander B. Dillon |
title |
Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies |
title_short |
Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies |
title_full |
Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies |
title_fullStr |
Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies |
title_full_unstemmed |
Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies |
title_sort |
immunotherapy in melanoma, gastrointestinal (gi), and pulmonary malignancies |
publisher |
AIMS Press |
series |
AIMS Public Health |
issn |
2327-8994 |
publishDate |
2015-03-01 |
description |
Oncologic immunotherapy involves stimulating the immune system to more effectively identify and eradicate tumor cells that have successfully adapted to survive the body's natural immune defenses. Immunotherapy has shown great promise thus far by prolonging the lives of patients with a variety of malignancies, and has added a crucial new set of tools to the oncologists' armamentarium. The aim of this paper is to provide an overview of immunotherapy treatment options that are currently available and under active research for melanoma, gastrointestinal (esophageal, gastric, pancreatic, and colorectal), and pulmonary malignancies. Potential biomarkers that may predict favorable responses to immunotherapies are discussed where applicable, as are future avenues of research in this rapidly evolving field. |
topic |
immunotherapy melanoma esophageal cancer gastric cancer colorectal cancer lung cancer IL-2 adoptive cell therapy anti-CTLA-4 anti-PD-1 |
url |
http://www.aimspress.com/aimsph/article/226/fulltext.html |
work_keys_str_mv |
AT alexanderbdillon immunotherapyinmelanomagastrointestinalgiandpulmonarymalignancies AT kevinlin immunotherapyinmelanomagastrointestinalgiandpulmonarymalignancies AT andrewkwong immunotherapyinmelanomagastrointestinalgiandpulmonarymalignancies AT susanaortiz immunotherapyinmelanomagastrointestinalgiandpulmonarymalignancies |
_version_ |
1725926625895251968 |